Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer.

Shu-Qiang YuanRun-Cong NieYou-Sheng HuangYing-Bo ChenSi-Yu WangXiao-Wei SunYuan-Fang LiZe-Kun LiuYan-Xing ChenYi-Chen YaoYu XuHai-Bo QiuYao LiangWei WangZe-Xian LiuQi Zhao Rui-Hua XuZhi-Wei ZhouFeng-Hua Wang

Published in: Cancer communications (London, England) (2023)

Residual ctDNA after ACT effectively predicts high recurrence risk in stage II/III GC, and the combination of tissue-based and circulating tumor features could achieve better risk prediction.

Keyphrases

circulating tumor
cell free
circulating tumor cells
free survival
mass spectrometry
high resolution